carbamazepine and valproic acid

Carbamazepine induces hepatic enzymes, including CYP3A4 and glucuronyl transferases, which increases the metabolism and clearance of valproic acid, lowering its serum levels. Valproic acid inhibits carbamazepine epoxide hydrolase, causing accumulation of carbamazepine-10,11-epoxide, the active metabolite of carbamazepine. Valproic acid may also displace carbamazepine from plasma protein binding, transiently increasing free carbamazepine levels.

Reduced valproic acid concentrations may lead to loss of seizure control. Elevated carbamazepine epoxide concentrations may cause carbamazepine toxicity, including nystagmus, ataxia, diplopia, somnolence, and dizziness. The severity of these effects varies, and fatalities have been reported in cases of severe toxicity. This is a bidirectional interaction affecting both safety and efficacy.

Monitor serum concentrations of both valproic acid and carbamazepine (including free carbamazepine if feasible) at baseline and after any dose change, and monitor for clinical signs of toxicity or inadequate seizure control. Adjust valproic acid dose upwards if levels fall, and consider reducing carbamazepine dose if epoxide toxicity develops. Consider alternative antiepileptic drugs if monitoring is not available or if the interaction proves difficult to manage.

Well-established clinical and pharmacokinetic interaction, supported by multiple controlled studies and case reports. The interaction is recognised in standard formularies and prescribing information.